AI
ALXN

Atria Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Atria Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,873
Closed -$1.39M – 757
2020
Q4 		$1.39M Buy
8,873
+82
+0.9% +$10.5K 0.03% 548
2020
Q3 		$1.01M Buy
+8,791
New +$948K 0.03% 576
2020
Q2 		– Sell
-6,174
Closed -$554K – 807
2020
Q1 		$554K Buy
6,174
+490
+9% +$48.1K 0.04% 331
2019
Q4 		$615K Buy
5,684
+2,909
+105% +$311K 0.02% 707
2019
Q3 		$272K Sell
2,775
-1,536
-36% -$173K 0.01% 749
2019
Q2 		$470K Buy
4,311
+2,114
+96% +$272K 0.02% 603
2019
Q1 		$297K Sell
2,197
-154
-7% -$19.1K 0.01% 708
2018
Q4 		$229K Sell
2,351
-503
-18% -$59.5K 0.01% 764
2018
Q3 		$397K Buy
2,854
+122
+4% +$15.3K 0.02% 671
2018
Q2 		$339K Buy
2,732
+488
+22% +$57K 0.01% 699
2018
Q1 		$250K Buy
2,244
+98
+5% +$11.7K 0.01% 735
2017
Q4 		$257K Buy
2,146
+324
+18% +$39.5K 0.01% 706
2017
Q3 		$256K Buy
+1,822
New +$248K 0.01% 658
2017
Q2 		– Sell
-2,456
Closed -$298K – 801
2017
Q1 		$298K Sell
2,456
-224
-8% -$28.9K 0.02% 517
2016
Q4 		$328K Buy
2,680
+429
+19% +$52.5K 0.03% 444
2016
Q3 		$276K Buy
+2,251
New +$290K 0.03% 421

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atria Investments's ALXN Position: Q1 2021 in Review

Atria Investments sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 8,873 shares — an estimated $1.39M sold.

Atria Investments first reported a position in ALXN in Q3 2016 and held it in 16 quarters. The position peaked at $1.39M in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Atria Investments reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Atria Investments sold 8,873 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.39M.
  • Atria Investments first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 16 quarters.
  • Atria Investments's Alexion Pharmaceuticals position peaked at $1.39M in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Atria Investments's 13F filing for Q1 2021, filed 11 May 2021.